Women's Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy

News provided by

Nov 19, 2012, 06:51 ET

NEW YORK, Nov. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Women's Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy

http://www.reportlinker.com/p01041700/Women's-Health-Therapeutics-Market-to-2018---Unmet-Need-for-Safe-and-Effective-Treatments-due-to-Unfavorable-Risk/Benefit-Profile-Associated-with-Hormone-Replacement-Therapy.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Women's Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy

Summary Europe Germany France Italy Spain Japan India China Australia

In 2011, the women's health therapeutics market was estimated to be worth $18.8 billion. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of 2.7% between 2011 and 2018, to record a sales value of $22.7 billion in 2018. The patent expiries of blockbusters such as Evista, the Premarin family, Forteo, Mirena, Boniva, Actonel, Gonal-F and others during the forecast period are expected to slow down the market growth for the women's health therapeutics market. The launch of novel molecules like Elagolix and Odanacatib in the late stage pipeline will drive the market in the forecast period.

The women's health therapeutics market R&D pipeline shows promising molecules. The current treatment options for women's disorders are limited due to lack of safety. The unmet need in the women's disorders market is attracting the pharmaceutical companies to invest in R&D programs. Increased focus is seen on therapy areas such as menopause, female sexual dysfunction and infertility.

Scope

- Analysis of the leading therapeutic segments, including menopause, postmenopausal osteoporosis, endometriosis, infertility, and the female contraceptives market.

- Analysis of the women's health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.

- Market characterization of the women's health therapeutics market, including market size, annual cost of therapy and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, F. Hoffman-La Roche Ltd., Merck, Bayer and Warner Chilcott Plc.

- Key M&A activities and licensing agreements that took place in the years 2010 to 2012 in the women's health therapeutics market.

Reasons to buy

- Develop market entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents1 Table of Contents 51.1 List of Tables 81.2 List of Figures 102 Women's Health Therapeutics Market to 2018 - Introduction 122.1 Overview 123 Women's Health Therapeutics Market to 2018 - Market Overview 133.1 Introduction 133.2 Revenue Forecasts for the Women's Health Therapeutics Market 143.2.1 Revenues 143.2.2 Annual Cost of Therapy 153.2.3 Branded and Generic Market Share 163.3 Treatment Usage Patterns 173.4 Drivers and Barriers for the Women's Health Therapeutics Market 193.4.1 Drivers for the Women's Health Therapeutics Market 193.4.2 Barriers for the Women's Health Therapeutics Market 194 Women's Health Therapeutics Market to 2018 - Geographical Landscape 204.1 The US 204.1.1 Revenue 204.1.2 Annual Cost of Therapy 214.1.3 Treatment Usage Pattern 224.2 Top Five Countries of Europe 234.2.1 Revenue 234.2.2 Annual Cost of Therapy 254.2.3 Treatment Usage Pattern 264.3 Japan 274.3.1 Revenue 274.3.2 Annual Cost of Therapy 284.3.3 Treatment Usage Pattern 294.4 Women's Health Therapeutics Market, Australia - Overview 304.4.1 Epidemiology 304.4.2 Clinical Trials 304.4.3 Drivers and Restraints 314.5 Women's Health Therapeutics Market, India - Overview 314.5.1 Epidemiology 314.5.2 Clinical Trials 324.5.3 Drivers and Restraints 324.6 Women's Health Therapeutics Market, China - Overview 334.6.1 Epidemiology 334.6.2 Clinical Trials 334.6.3 Drivers and Restraints 345 Women's Health Therapeutics Market to 2018 - Therapeutic Landscape 355.1 Menopause 355.1.1 Introduction 355.1.2 Revenues 365.1.3 Branded and Generic Market Share 385.1.4 Annual Cost of Therapy 395.1.5 Treatment Usage Patterns 405.1.6 Major Marketed Products in the Menopause Therapeutics Market 415.1.7 Drivers for the Menopause Therapeutics Market 445.1.8 Barriers for the Menopause Therapeutics Market 455.2 Postmenopausal Osteoporosis 455.2.1 Introduction 455.2.2 Revenues 465.2.3 Branded versus Generic Market Share 485.2.4 Annual Cost of Therapy 495.2.5 Treatment Usage Patterns 505.2.6 Treatment Flow Algorithm 525.2.7 Major Marketed Drugs in the Postmenopausal Osteoporosis Market 535.2.8 Drivers for the Postmenopausal Osteoporosis Market 605.2.9 Barriers for the Postmenopausal Osteoporosis Market 615.3 Endometriosis 615.3.1 Introduction 615.3.2 Revenues 625.3.3 Branded and Generic Market Share 645.3.4 Annual Cost of Therapy 655.3.5 Treatment Usage Patterns 665.3.6 Treatment Flow Algorithm 675.3.7 Major Marketed Drugs for Endometriosis 685.3.8 Drivers for the Endometriosis Therapeutics Market 715.3.9 Barriers for the Endometriosis Therapeutics Market 725.4 Infertility 725.4.1 Introduction 725.4.2 Revenues 735.4.3 Branded and Generic Market Share 755.4.4 Annual Cost of Therapy 765.4.5 Treatment Usage Patterns 775.4.6 Treatment Flow Algorithm 785.4.7 Major Marketed Drugs in the Infertility Therapeutics Market 795.4.8 Drivers for the Infertility Therapeutics Market 845.4.9 Barriers for the Infertility Therapeutics Market 855.5 Female Contraceptives 855.5.1 Introduction 855.5.2 Revenues 875.5.3 Share of Prescription and OTC Contraceptives 905.5.4 Annual Cost of Usage 915.5.5 Treatment Usage Patterns 925.5.6 Major Marketed Products in the Female Contraceptives Market 935.5.7 Drivers for the Female Contraceptives Market 955.5.8 Barriers for the Female Contraceptives Market 966 Women's Health Therapeutics Market to 2018 - Pipeline Analysis 976.1 Overview 976.2 Research and Development Pipeline - Menopause 996.2.1 Overview 996.3 Research and Development Pipeline - Postmenopausal Osteoporosis 996.3.1 Overview 996.4 Research and Development Pipeline - Endometriosis 1006.4.1 Overview 1006.5 Research and Development Pipeline - Infertility 1006.5.1 Overview 1006.6 Research and Development Pipeline - Female Sexual Dysfunction 1016.6.1 Overview 1016.7 Research and Development Pipeline - Contraceptives 1026.7.1 Overview 1026.8 Profiles of Promising Drugs in the Women's Health Therapeutics Market 1036.8.1 Menerba 1036.8.2 Odanacatib 1046.8.3 Elagolix 1056.8.4 Libigel 1066.8.5 Femprox 1076.8.6 MK 8962 1086.8.7 Zoely 1096.8.8 AMG 785 1107 Women's Health Therapeutics Market to 2018 - Competitive Landscape 1117.1 Market Share Analysis: Women's Health Therapeutics Market 1117.2 Competitive Profiling 1127.2.1 Warner Chilcott 1127.2.2 Pfizer 1137.2.3 Eli-Lilly 1157.2.4 Merck 1167.2.5 Roche 1187.2.6 Bayer 1198 Women's Health Therapeutics Market to 2018 - Strategic Consolidations 1208.1 Overview 1208.2 Deals by Year 1208.3 Deals by Type 1218.4 Deals by Value 1218.5 Mergers and Acquisitions 1228.5.1 Major M&A Deals 1248.6 Licensing Agreements 1258.6.1 Major Licensing Agreements 1278.7 Partnerships 1288.7.1 Major Partnership Deals 1299 Women's Health Therapeutics Market to 2018 - Appendix 1309.1 Abbreviations 1309.2 Market Definitions 1319.3 Bibliography 1319.4 Research Methodology 1329.4.1 Coverage 1339.4.2 Secondary Research 1339.4.3 Primary Research 1339.4.4 Expert Panel Validation 1349.4.5 Section-wise Research Methodology 1349.5 Therapeutic Landscape 1349.5.2 Market Size by Geography 1369.6 Geographical Landscape 1379.7 Pipeline Analysis 1379.8 Competitive Landscape 1379.9 Strategic Consolidations 1379.10 Contact Us 1379.11 Disclaimer 137

1.1 List of Tables

Table 1: Women's Health Therapeutics Market, Global, Revenue ($bn), 2003-2011 14Table 2: Women's Health Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 14Table 3: Women's Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011 15Table 4: Women's Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 15Table 5: Women's Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 17Table 6: Women's Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 17Table 7: Women's Health Therapeutics Market, The US, Revenue ($bn), 2003-2011 20Table 8: Women's Health Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018 20Table 9: Women's Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2011 21Table 10: Women's Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2018 21Table 11: Women's Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2003-2011 22Table 12: Women's Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2018 22Table 13: Women's Health Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2003-2011 23Table 14: Women's Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018 24Table 15: Women's Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2011 25Table 16: Women's Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2011-2018 25Table 17: Women's Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2003-2011 26Table 18: Women's Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2011-2018 26Table 19: Women's Health Therapeutics Market, Japan, Revenue ($m), 2003-2011 27Table 20: Women's Health Therapeutics Market, Japan, Revenue Forecasts ($m), 2011-2018 27Table 21: Women's Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2011 28Table 22: Women's Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018 28Table 23: Women's Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2003-2011 29Table 24: Women's Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2018 29Table 25: Women's Health Therapeutics Market, Pipeline Molecules, Australia, 2012 30Table 26: Women's Health Therapeutics Market, Pipeline Molecules, India, 2012 32Table 27: Women's Health Therapeutics Market, Pipeline Molecules, China, 2012 33Table 28: Menopause Therapeutics Market, Global, Revenue ($m), 2003-2011 36Table 29: Menopause Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 36Table 30: Menopause Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011 37Table 31: Menopause Therapeutics Market, Global, Revenue by Geography ($m), 2011-2018 38Table 32: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011 39Table 33: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 39Table 34: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 40Table 35: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 40Table 36: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2003-2011 46Table 37: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 46Table 38: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2003-2011 47Table 39: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2011-2018 48Table 40: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011 49Table 41: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 49Table 42: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 50Table 43: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 50Table 44: Postmenopausal Osteoporosis Therapeutics Market, Major Marketed Drug Revenues, 2011 53Table 45: Endometriosis Therapeutics Market, Global, Revenue ($m), 2003-2011 62Table 46: Endometriosis Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 62Table 47: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011 63Table 48: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2011-2018 64Table 49: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011 65Table 50: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 65Table 51: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 66Table 52: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 66Table 53: Infertility Therapeutics Market, Global, Revenue ($m), 2003-2011 73Table 54: Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 73Table 55: Infertility Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011 74Table 56: Infertility Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2011-2018 75Table 57: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011 76Table 58: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 76Table 59: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 77Table 60: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 77Table 61: Infertility Therapeutics Market, Major Marketed Drug Revenues ($m), 2011 79Table 62: Efficacy Outcome by Treatment Groups in Ovulation Induction for Study FPI FSH 99-03 (One Cycle of Treatment) 83Table 63: Efficacy Outcome for IVF Study FPI FSH 2001-01 (One Cycle of Treatment) 84Table 64: Contraceptives Market, Global, Revenue ($bn), 2003-2011 87Table 65: Contraceptives Market, Global, Revenue Forecasts ($bn), 2011-2018 87Table 66: Contraceptives Market, Global, Revenue by Type ($m), 2003-2011 88Table 67: Contraceptives Market, Global, Revenue Forecasts by Type ($m), 2011-2018 88Table 68: Contraceptives Market, Global, Revenue by Geographical Segmentation ($m), 2003-2011 89Table 69: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 90Table 70: Contraceptives Market, Global, Annual Cost of Usage ($), 2003-2011 91Table 71: Contraceptives Market, Global, Annual Cost of Usage ($), 2011-2018 91Table 72: Contraceptives Market, Global, Treatment Usage Patterns (million), 2003-2011 92Table 73: Contraceptives Market, Global, Treatment Usage Patterns (million), 2011-2018 92Table 74: Contraceptives Market, Major Marketed Drug Market Share, 2011 93Table 75: Women's Health Therapeutics Market, Global, Pipeline by Phase (%), 2012 97Table 76: Women's Health Therapeutics Market, Global, Pipeline by Indication (%), 2012 98Table 77: Women's Health Therapeutics Market, Global, Pipeline Analysis, Most Promising Molecules, 2012 103Table 78: Women's Health Therapeutics Market, Warner Chilcott, Major Marketed Products, 2011 112Table 79: Women's Health Therapeutics Market, Pfizer, Major Marketed Products, 2011 114Table 80: Women's Health Therapeutics Market, Eli Lilly, Major Marketed Products, 2011 115Table 81: Women's Health Therapeutics Market, Merck, Major Marketed Products, 2011 116Table 82: Women's Health Therapeutics Market, Roche, Major Marketed Products, 2011 118Table 83: Women's Health Therapeutics Market, Bayer, Major Marketed Products, 2011 119Table 84: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Mergers and Acquisitions, 2010-2012 122Table 85: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Agreements, 2010-2012 125Table 86: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Partnerships, 2010-2012 128

1.2 List of Figures

Figure 1: Women's Health Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2018 14Figure 2: Women's Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018 15Figure 3: Women's Health Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 16Figure 4: Women's Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 17Figure 5: Women's Health Therapeutics Market, Global, Drivers and Barriers 19Figure 6: Women's Health Therapeutics Market, The US, Revenue Forecasts ($bn), 2003-2018 20Figure 7: Women's Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2018 21Figure 8: Women's Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2003-2018 22Figure 9: Women's Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2003-2018 23Figure 10: Women's Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2018 25Figure 11: Women's Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2003-2018 26Figure 12: Women's Health Therapeutics Market, Japan, Revenue Forecasts ($m), 2003-2018 27Figure 13: Women's Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2018 28Figure 14: Women's Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2003-2018 29Figure 15: Menopause Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018 36Figure 16: Menopause Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018 37Figure 17: Menopause Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 38Figure 18: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018 39Figure 19: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 40Figure 20: Menopause Therapeutics Market, Global, Drivers and Barriers 44Figure 21: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2018 46Figure 22: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2003-2018 47Figure 23: Postmenopausal Osteoporosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 48Figure 24: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018 49Figure 25: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 50Figure 26: Postmenopausal Osteoporosis Therapeutics Market, Treatment Flow Algorithm 52Figure 27: Postmenopausal Osteoporosis Therapeutics Market, Major Marketed Drug Market Share, 2011 53Figure 28: Postmenopausal Osteoporosis Therapeutics Market, Global, Drivers and Barriers 60Figure 29: Endometriosis Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018 62Figure 30: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018 63Figure 31: Endometriosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 64Figure 32: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018 65Figure 33: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 66Figure 34: Endometriosis Therapeutics Market, Treatment Flow Algorithm 67Figure 35: Endometriosis Therapeutics Market, Global, Drivers and Barriers 71Figure 36: Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018 73Figure 37: Infertility Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018 74Figure 38: Infertility Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 75Figure 39: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018 76Figure 40: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 77Figure 41: Infertility Therapeutics Market, Treatment Flow Algorithm 78Figure 42: Infertility Therapeutics Market, Global, Drivers and Barriers 84Figure 43: Contraceptives Market, Global, Revenue Forecasts ($bn), 2003-2018 87Figure 44: Contraceptives Market, Global, Revenue Forecasts by Type ($m), 2003-2018 88Figure 45: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2003-2018 89Figure 46: Contraceptives Market, Global, Share of Prescription and OTC Contraceptives (%), 2011 90Figure 47: Contraceptives Market, Global, Annual Cost of Usage ($), 2003-2018 91Figure 48: Contraceptives Market, Global, Treatment Usage Patterns (million), 2003-2018 92Figure 49: Contraceptives Market, Major Marketed Drug Market Share, 2011 93Figure 50: Contraceptives Market, Global, Drivers and Barriers 95Figure 51: Women's Health Therapeutics Market, Global, Pipeline by Phase (%), 2012 97Figure 52: Women's Health Therapeutics Market, Global, Pipeline by Indication (%), 2012 98Figure 53: Menopause Therapeutics Market, Global, Pipeline by Phase (%), 2012 99Figure 54: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline by Phase (%), 2012 99Figure 55: Endometriosis Therapeutics Market, Global, Pipeline by Indication (%), 2012 100Figure 56: Infertility Therapeutics Market, Global, Pipeline by Indication (%), 2012 100Figure 57: Female Sexual Dysfunction Therapeutics Market, Global, Pipeline by Indication (%), 2012 101Figure 58: Female Contraceptives Market, Global, Pipeline by Indication (%), 2012 102Figure 59: Women's Health Therapeutics Market, Global, Market Share of Companies (%), 2011 111Figure 60: Women's Health Therapeutics Market, Warner Chilcott SWOT Analysis, 2012 113Figure 61: Women's Health Therapeutics Market, Pfizer SWOT Analysis, 2012 114Figure 62: Women's Health Therapeutics Market, Eli Lilly SWOT Analysis, 2012 115Figure 63: Women's Health Therapeutics Market, Merck SWOT Analysis, 2012 117Figure 64: Women's Health Therapeutics Market, Roche SWOT Analysis, 2012 118Figure 65: Women's Health Therapeutics Market, Bayer SWOT Analysis, 2012 119Figure 66: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Year, 2010-2012 120Figure 67: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type, 2010-2012 121Figure 68: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value, 2010-2012 121Figure 69: GBI Research Market Forecasting Model 136

Companies mentioned

Warner Chilcott

Pfizer

Eli-Lilly

Merck

Roche

Bayer

To order this report:Therapy Industry: Women's Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626